Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camu Camu Prebiotic with ICI in NSCLC and Melanoma
NCT05303493Phase 1Completed
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Jun 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of myrciaria dubia in non-small cell lung cancer (NSCLC) and melanoma (3 cohorts), sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoint: Incidence of treatment-related adverse events at 2 years. Started Jun 2022; status: completed.
02
Drugs
myrciaria dubia
03
Conditions
non-small cell lung cancer (NSCLC)melanoma
Beyond the preview
Go deeper on NCT05303493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05303493.